Group Leader/s



The Translational medicinal and biological chemistry group is focused on the design, synthesis, biological evaluation, study and further optimization of pharmacokinetic properties of structurally diverse chemical entities for drug discovery. The efforts of our group are focused on the discovery of innovative drugs with novel mechanism of action as disease-modifying agents for unmet severe pathologies such as neurodegenerative and neglected diseases. Our group applies medicinal chemistry programs combining classical and computational medicinal chemistry.

For the design of our drugs (mainly small heterocyclic molecules with MW<500), different strategies will be used. These include computer-aided drug design, multifunctional compounds bearing different pharmacophore moieties in the same molecule to interact with different targets, and improving ADME properties of the candidates, among others. The group has developed an in-house chemical library (called MBC library) containing over 1200 compounds with privileged scaffolds, which is continuously growing and extensively used in our directed biological and computational screening programs.

Our research is applied with a high content of translational research. The group's research programs are designed from the early stages of drug discovery to proof of efficacy in representative animal models. Scientific collaborations and technology transfer to companies in the pharmaceutical sector are key tasks in achieving our goals.





Mansilla, A.; Chavez-Sanjuán, A.; Campillo, N. E.; Semelidou, O.; Infantes, L.; Gil, C.; Conde, S.; Skoulakis, E. M. C.; Ferrús, A.; Martinez, A.; Sánchez-Barrena, M. J.  [2017]. Phenothiazines regulate synaptic function by interfering the NCS-1/Ric8a complex: a novel approach for Fragile X Syndrome. PNAS 2017, 114, E999-E1008.

Ed. A. Martinez and C. Gil.  [2017]. Comprehensive Medicinal Chemistry III Ed. Vol 1: General Perspectives-The future of Drug Discovery. Ed. A. Martinez and C. Gil. Elsevier. 2017, ISBN 9780128032008

Palomo, V.; Martinez, A.  [2017]. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin. Ther. Pat. 2017, 27, 657-666.

Monjas, L.; Arce, M. P.; León, R.; Egea, J.; Pérez, C.; Villarroya, M.; López, M. G.; Gil, C.; Conde, S.; Rodríguez-Franco, M. I.  [2017]. Enzymatic and solid-phase synthesis of new donepezil-based L- and D-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. Eur. J. Med. Chem. 2017, 130, 60-72.

Roca, C.; Sebastián-Pérez, V.; Campillo, N. E.  [2017]. "In silico Tools for Target Identification and Drug Molecular Docking in Leishmania" en Drug Discovery for Leishmaniasis. Ed. L. Rivas and C. Gil. Royal Society of Chemistry. 2017, 130-152

Chierrito, T.; Pedersoli-Mantoani, S.; Roca, C.; Requena, C.; Sebastian-Perez, V.; Castillo, W.; Moreira, N.; Perez, C.; Sakamoto, E.; Takashashi, C.; Jimenez-Barbero, J.; Cañada, F.J.; Campillo, N.E.; Martinez, A.; Carvalho, I.  [2017]. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer’s disease. Eur. J. Med. Chem. 2017, 39, 773-791

Contreras, A.; Del Rio, D.; Martinez, A.; Gil, C.; Morales, L.; Ruiz-Gayo, M.; Del Olmo, N.  [2017]. Inhibition of hippocampal long-term potentiation by high-fat diets: is it related to an effect of palmitic acid involving glycogen synthase kinase-3?. Neuroreport 2017, 28, 354-359.

Pardo, M.; Cheng, Y.; Velmeshev, D.; Magistri, M.; Eldar-Finkelman, H.; Martinez, A.; Faghihi, M.; Jope, R.S.; Beurel, E.  [2017]. Intranasal siRNA administration can regulate learning and ameliorate deficits in Fragile X syndrome mice. J Clinical Investigation Insight, 2017, 2(6):e91782.

Garcia, A. M.; Salado, I. G.; Perez, D. I.; Brea, J.; Morales-García, J. M.; González-García, A.; Cadavid, M. I.; Loza, M. I.; Luque, F. J.; Perez-Castillo, A.; Martinez, A.; Gil, C.  [2017]. New pharmacological tools based on imidazole scaffold proved the utility of Phosphodiesterase 10 (PDE10) inhibitors for Parkinson’s disease treatment. Fut. Med. Chem. 2017, 9, 707-810.

Huang, S.; Wang, H.T.; Abussaud, A.; Turlova, E.; Ji, P.; Martinez, A.; Sun, H.S.; Feng, Z.P.  [2017]. GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice. CNS Neurosci. & Therapeutics, 2017, 23, 405-415.




Multitarget-designed small molecules targeting protein kinase and BACE1: A new approach for prevention and treatment of cognitive disorders (SAF2016-76693-R)

01.01.2017 - 31.12.2019
PI: Dr. Ana Martinez

Strengthening the druggability of protein kinases of Leishmania. Drug discovery of specific parasite protein kinase inhibitors (SAF2015-65740-R)

01.01.2016 - 31.12.2018
PIs: Drs. Carmen Gil and Luis Rivas

From fragments to hits: Exploiting the potential of dynamic combinatorial chemistry in drug discovery (CTQ2015-69643-R)

01.01.2016 - 31.12.2018
PI: Dr. Ruth Pérez Fernández

Chemi-computation to discovery of multitarget drugs for the treatment of Alzheimer's disease (CTQ2015-66313-R)

01.01.2016 - 31.12.2018
PI: Drs. Nuria E. Campillo and Angeles Martín Requero

Eyes: a diagnosis window to the brain (SAF2015-72325-EXP)

01.06.2016 - 31.05.2017
PI: Dr. A. Martinez

Development of innovative therapies for Parkinson’s disease (RTC-2015-3439-1).

01.70-2015 – 31.12-2018
PI: Dr. Ana Martinez

Spanish network of drug discovery (SAF2015-71892-REDT).

MINECO, Redes de Excelencia Program
01.01.-2016 – 31.12.2017
PI (CSIC): Dr. Ana Martínez

Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target neglected parasitic diseases-PDE4NPD (GA 602666)

UE, FP7-Health Program
1.03.2014 - 28.02.2018
Coordinator: Prof. Rob Leurs (VUA). PI (CSIC): Dr. Carmen Gil

Kinase inhibitors for the treatment of amyotrophic lateral sclerosis (SAF2012-37979-C03-01).

01.01.2013 - 31.12.2016
PI: Dr. Ana Martinez


New pharmacological approaches for Parkinson’s disease treatment (SAF2012-33600)

01.01.2013 - 30.06.2016
PI: Dr. Carmen Gil

Novel potential anti-Alzheimer agents: From design to preclinical studies (i-link0801).

CSIC, i-LINK Program
01.01.2014 - 30.06.2016
PI: Dr. Ana Martinez

Phosphodiesterase inhibitors as potential drugs for the treatment of Parkinson’s disease (PIE-201280E087).

CSIC, Proyectos Intramurales Especiales.
01.06.2012 - 30.05.2015
PI: Dr. Carmen Gil

Development of innovative therapies for the treatment of Parkinson’s disease (IPT-2012-0762-300000)

01.7.2012 - 31.12.2015
Coordinator: Dr. Manuel Sarasa (ARACLON).  PI (CSIC): Dr. Ana Martinez.


More info

Outreach activities


Pint of Science (

Title: Cómo ser un fármaco y no morir en el intento
Carmen Gil and Nuria E. Campillo   

Location: Madrid
Date: 24 Mayo 2016             



“¿Qué sabemos de?” institutional program (

Title: Parkinson y Alzheimer: avances en el tratamiento
Ana Martinez

Location: Lanzarote
Date: 24 Mayo 2016



Title: Parkinson y Alzheimer: avances en el tratamiento
Ana Martinez

Location: Fuerteventura
Date: 25 Mayo 2016


Title: Ciencia y emprendimiento: del laboratorio a la farmacia
Ana Martinez

Location: Madrid
Date: 14 Enero 2016


“Primavera para el recuerdo”
Title: ¿Qué sabemos del Alzheimer? (

Ana Martinez

Location: Huesca
Date: 6 Mayo 2016


“Ciudad Ciencia” institutional program (

Title: ¿Que sabemos del Alzheimer?
Ana Martinez

Location: Plasencia
Date: 13 April 2015


Title: ¿Qué sabemos del Parkisnon?
Ana Martinez

Location: Barbastro
Date: 26 November 2015


Title: ¿Qué sabemos del Parkisnon?
Ana Martinez

Location: Valdepeñas
Date: 10 December 2015



Title: ¿Qué sabemos del Alzheimer?
Ana Martinez
Editorial: CSIC and Catarata ISBN: 978-84-00-08818-7

Title: ¿Qué sabemos del Parkinson?
Carmen Gil and Ana Martinez
Editorial: CSIC and Catarata ISBN: 978-0-470-95917-6.
















10-13/11/2015 Science Week
“Paracetamol synthesis” Hands on workshop with more than 80 High School students.